-+ 0.00%
-+ 0.00%
-+ 0.00%
Sobi Wins Expanded Approval for Tryngolza in EU
Share
Listen to the news
03:50 AM EST, 11/17/2026 (MT Newswires) -- Swedish Orphan Biovitrum (SOBI.ST), or Sobi, received approval from the European Commission for the expanded use of Tryngolza in adult patients with severe hypertriglyceridaemia, alongside diet and other lipid-lowering therapies. The biopharmaceutical company holds exclusive rights to commercialize the drug outside the US, except in Canada and China, under a licensing agreement with its US-based developer Ionis Pharmaceuticals, according to a Tuesday release. The latest approval was supported by results from phase 3 Core and Core2 studies, which showed a statistically significant reduction of up to 73% in triglyceride levels at six months compared with placebo among patients with baseline levels of at least 880 milligrams per deciliter. The reductions were sustained through 12 months. Tryngolza was already approved in the European Union for familial chylomicronemia syndrome.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending